BiotechTube
MetrioPharm

MetrioPharm

Zürich, Switzerland· Est.
metriopharm.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12.4M

Overview

MetrioPharm is a private, clinical-stage biotech developing first-in-class oral therapeutics that modulate macrophage activity to treat inflammatory and fibrotic conditions. Its lead candidate, MP1032, is a small molecule with a unique dual mechanism targeting reactive oxygen species (ROS) and the NLRP3 inflammasome, positioning it for diseases like pulmonary fibrosis and psoriasis. The company is pre-revenue, having advanced its pipeline through private funding and strategic partnerships, and faces a competitive but high-value market with significant unmet medical need.

Inflammatory DiseasesFibrotic Diseases

Technology Platform

Small molecule platform based on Methysticin derivatives (e.g., MP1032) with a dual mechanism: induces cellular phase 2 antioxidant response and selectively inhibits the NLRP3 inflammasome to modulate macrophage function from pro-inflammatory to pro-resolving states.

Funding History

2
Total raised:$12.4M
Grant$2.4M
Series A$10M

Opportunities

The large, underserved markets for fibrotic diseases like IPF and chronic inflammatory conditions present a multi-billion dollar opportunity.
Success with its oral NLRP3 inhibitor could position MetrioPharm as an attractive partner or acquisition target for larger pharmaceutical companies seeking novel immunology assets.
The platform's potential applicability across multiple NLRP3-driven diseases offers significant expansion potential.

Risk Factors

The primary risk is clinical failure of its lead candidate, MP1032, in ongoing or future trials.
As a pre-revenue private company, it faces significant financing risk to fund expensive late-stage development.
It also operates in the highly competitive NLRP3 inhibitor space against well-resourced competitors.

Competitive Landscape

MetrioPharm competes in the rapidly evolving field of NLRP3 inflammasome inhibitors, which includes candidates from both biotechs and large pharma. In fibrosis, it faces competition from approved anti-fibrotics and a pipeline of novel mechanisms. Its differentiation lies in the oral small molecule format and dual antioxidant/inflammasome mechanism, but it must demonstrate superior efficacy or safety to gain traction.

More companies in Switzerland →